Evidence map›Paper›PMID 31246975›Full record

ArticlePloS one2019

A new microbial gluten-degrading prolyl endopeptidase: Potential application in celiac disease to reduce gluten immunogenic peptides.

María de Lourdes Moreno Amador, Miguel Arévalo-Rodríguez, Encarnación Mellado Durán, Juan Carlos Martínez Reyes, Carolina Sousa Martín

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. World journal of gastroenterology · 2024
    Article
  3. Review
  4. Article
  5. Iranian journal of biotechnology · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Replacing the Burden of the Gluten Free Diet: Then, Now, and the Future.International journal of molecular sciences · 2022
    Review
  10. Article
  11. Characterization ofFoods (Basel, Switzerland) · 2021
    Article
  12. Review
  13. Review
  14. Gluten-degrading bacteria: availability and applications.Applied microbiology and biotechnology · 2021
    Review
  15. Review
  16. Microbiome of root vegetables-a source of gluten-degrading bacteria.Applied microbiology and biotechnology · 2020
    Article
  17. The potentials of probiotics on gluten hydrolysis; a review study.Gastroenterology and hepatology from bed to bench · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

María de Lourdes Moreno AmadorDepartamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain.ORCID 0000-0002-7490-2037
Miguel Arévalo-RodríguezBiomedal S.L., Sevilla, Spain.
Encarnación Mellado DuránDepartamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain.
Juan Carlos Martínez ReyesBiomedal S.L., Sevilla, Spain.
Carolina Sousa MartínDepartamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain.
Universidad de Sevilla · ESBiomedal (Spain) · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gluten is a complex of proteins present in barley, wheat, rye and several varieties of oats that triggers celiac disease in genetically predisposed subjects. Gluten is notoriously difficult to digest by mammalian proteolytic enzymes and therefore, proline-rich digestion-resistant peptides contain multiple immunogenic epitopes. Prolyl endopeptidases (PEP) hydrolyse internal proline residues on the carboxyl side of peptides and have been proposed for food gluten detoxification and as oral enzyme supplementation for celiacs. The aim of this study was to identify new gluten-degrading microbial enzymes with the potential to reduce gluten immunogenicity by neutralizing its antigenic epitopes. Using a gluten-degrading colony screening approach, a bacterial isolate (2RA3) displaying the highest glutenase activity was selected, characterized and its genome completely sequenced. The identification through 16S rDNA gene sequencing showed a 99,1% similarity to Chryseobacterium taeanense. Hydrolysis of gluten immunogenic peptides (GIP) was further monitored, over a 48-hour period, by colony encapsulation in gliadin-containing microspheres, followed by detection with the G12 anti-GIP monoclonal antibody. Glutenase activity was detected in the extracellular medium of 2RA3 cultures, where gel electrophoresis and gliadin zymography revealed the presence of a ~50 kDa gluten-degrading enzyme. Nano-ESI-Q-TOF of the excised active band identified 7 peptides contained in the protein product predicted for an open reading frame (ORF) in the 2RA3 genome. Based on sequence similarity to the PEP family, the new enzyme was named PEP 2RA3. The PEP 2RA3 coding sequence was PCR-amplified from C. taeanense 2RA3, cloned and expressed in Escherichia coli as a C-terminally His-tagged recombinant protein and purified by Ni-NTA affinity chromatography. The recombinant protein, with predicted molecular mass and isoelectric point of 78.95 kDa and 6.8, respectively, shows PEP activity with standard chromogenic substrates, works optimally at pH 8.0 and 30°C and remains stable at pH 6.0 and 50°C, indicating a potential use in gluten-containing food process applications. The ability of the recombinant enzyme to degrade GIP in beer into smaller peptides was confirmed.

Indexed as

Amino Acid SequenceBacterial ProteinsCeliac DiseaseChryseobacteriumEnzyme ActivationGliadinGlutensHydrolysisMolecular WeightPeptidesProlyl OligopeptidasesRecombinant ProteinsSerine EndopeptidasesBacterial ProteinsGliadinGlutensPeptidesProlyl OligopeptidasesRecombinant ProteinsSerine Endopeptidases

Identifiers

PMID31246975
PMCPMC6597064
OpenAlexW2954114546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.